ORPHA:169799
Mild hemophilia B
Also known as: Mild congenital F9 deficiency · Mild congenital factor IX deficiency
Publications
141
54.7th percentile
Trials
0
Interventional, condition-specific
Researchers
789
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A mild form of hemophilia B characterized by a small deficiency of factor IX (biological activity between 5 and 40 IU/dL) leading to abnormal bleeding as a result of minor injuries or following trauma, surgery or tooth extraction. Spontaneous hemorrhages do not occur. The condition may affect males and female carriers of disease-causing mutations.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015717
- UMLS:C5679574
Additional Mondo synonyms (3)
mild factor IX deficiency · mild haemophilia type B · mild hemophilia type B
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
141 matched papers (82 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 120 for broader category hemophilia B
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
141
141 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
141 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
82 in the last 10 years · high confidence · 54.7th percentile (publications denominator)
Phrase hits: 141 · MeSH hits: 0
Who's working on it?
789
Distinct author names in 141 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bottema CD4 papers · 1991
Department of Biochemistry and Molecular Biology, Mayo Clinic/Foundation, Rochester, MN 55905.
Papers in Europe PMC - 02Fijnvandraat K4 papers · 2025
Pediatric Hematology Amsterdam UMC Emma Children's Hospital University of Amsterdam Amsterdam The Netherlands.
Papers in Europe PMC - 03Ketterling RP4 papers · 1991
Department of Biochemistry and Molecular Biology, Mayo Clinic/Foundation, Rochester, MN 55905.
Papers in Europe PMC - 04Ljung R4 papers · 2024
Department of Clinical Sciences and Paediatrics, Lund University, Lund, Sweden.
Papers in Europe PMC - 05Mancuso ME4 papers · 2023
Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Papers in Europe PMC - 06Peyvandi F4 papers · 2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.
Papers in Europe PMC - 07Sommer SS4 papers · 1991Papers in Europe PMC
- 08Königs C3 papers · 2024
Clinical and Molecular Hemostasis, Department of Pediatrics, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Papers in Europe PMC - 09Mannucci PM3 papers · 2025
Scientific Direction, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation and University of Milan, Italy.
Papers in Europe PMC - 10Monahan PE3 papers · 2015
1 Gene Therapy Center, University of North Carolina , Chapel Hill, NC 27599.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 120 trials are registered for hemophilia B, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 9 September 2026 · last trial check 9 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
120 interventional trials matched hemophilia B, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hemophilia B
120
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05611801·RECRUITING·A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT04647227·RECRUITING·SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Conditions: Hemophilia A With Inhibitor · Hemophilia B With Inhibitor·Matched via name phrase
- NCT05568719·RECRUITING·Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT04817462·RECRUITING·Liver Biopsy In Haemophilia Gene Therapy
Conditions: Hemophilia B, Severe · Hemophilia A, Severe·Matched via name phrase
- NCT07080905·RECRUITING·Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Conditions: Hemophilia B·Matched via name phrase
- NCT06120582·RECRUITING·Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)
Conditions: Hemophilia B·Matched via name phrase
- NCT07644832·RECRUITING·An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Conditions: Hemophilia A · Hemophilia B · Factor VII Deficiency·Matched via name phrase
- NCT05145127·RECRUITING·Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT03961243·NOT YET RECRUITING·Lentiviral FIX Gene Therapy
Conditions: Hemophilia B·Matched via name phrase
- NCT06700096·RECRUITING·An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Conditions: Hemophilia B·Matched via name phrase
- NCT05641610·RECRUITING·A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Conditions: Hemophilia B·Matched via name phrase
- NCT06747416·NOT YET RECRUITING·KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
Conditions: Hemophilia a and B·Matched via name phrase
- NCT05630651·RECRUITING·The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
Conditions: Hemophilia B·Matched via name phrase
- NCT05709288·RECRUITING·Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
Conditions: Hemophilia B·Matched via name phrase
- NCT06379789·RECRUITING·A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Conditions: Hemophilia B·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Mild hemophilia B — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mild hemophilia B" OR "Mild congenital F9 deficiency" OR "Mild congenital factor IX deficiency" OR "mild factor IX deficiency" OR "mild haemophilia type B" OR "mild hemophilia type B"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mild hemophilia B" OR "Mild congenital F9 deficiency" OR "Mild congenital factor IX deficiency" OR "mild factor IX deficiency" OR "mild haemophilia type B" OR "mild hemophilia type B"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemophilia B"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:29:13.193Z
